Quince Therapeutics Inc. (QNCX)
1.76
0.05 (2.92%)
At close: Jan 15, 2025, 3:59 PM
1.76
0.00%
After-hours Jan 15, 2025, 04:00 PM EST
Company Description
Quince Therapeutics, Inc., a biopharmaceutical company, focuses on advancing precision therapeutics for debilitating and rare diseases.
The company has discovered a broad bone-targeting drug platform to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease.
Its lead compound is NOV004, an anabolic peptide engineered to precisely target and concentrate at the bone fracture site The company was formerly known as Cortexyme, Inc. and changed its name to Quince Therapeutics, Inc. in August 2022.
Quince Therapeutics, Inc. was incorporated in 2012 and is headquartered in South San Francisco, California.
Quince Therapeutics Inc.
| Country | United States |
| IPO Date | May 9, 2019 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 32 |
| CEO | Dr. Dirk Thye M.D. |
Contact Details
Address: 601 Gateway Blvd South San Francisco, California United States | |
| Website | https://www.quincetx.com |
Stock Details
| Ticker Symbol | QNCX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001662774 |
| CUSIP Number | 22053A107 |
| ISIN Number | US22053A1079 |
| Employer ID | 90-1024039 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Dirk Thye M.D. | Chief Executive Officer, Chief Medical Officer & Director |
| Brendan Hannah M.B.A. | Chief Business Officer, Chief Operating Officer, Chief Compliance Officer and Principal Financial & Accounting Officer |
| Giovanni Mambrini M.Sc. | Chief Technology Officer |
| Dr. Charles S. Ryan J.D., Ph.D. | President |
| Dr. Guenter R. Janhofer M.D., Ph.D. | Chief Scientific Officer |
| Dr. Stewart A. Low Ph.D. | Head of Discovery |
| Mary Ellen Sillivos | Vice President of Human Resources |
| Pamela M. Williamson FRAPS, M.B.A., RAC | Head of Regulatory Affairs |
| Stacy Roughan | Vice President of Corporate Communications & Investor Relations |
| Thomas Sabia M.B.A. | Chief Commercial Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jan 08, 2025 | 4 | Filing |
| Jan 08, 2025 | 4 | Filing |
| Jan 08, 2025 | 4 | Filing |
| Jan 08, 2025 | 4 | Filing |
| Dec 27, 2024 | 424B5 | Filing |
| Dec 18, 2024 | S-3 | Filing |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Nov 14, 2024 | 8-K | Current Report |
| Nov 13, 2024 | SC 13D | Filing |
| Nov 13, 2024 | 10-Q | Quarterly Report |